HomeCompareSSREF vs ABBV

SSREF vs ABBV: Dividend Comparison 2026

SSREF yields 4.67% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $3.7K in total portfolio value
10 years
SSREF
SSREF
● Live price
4.67%
Share price
$158.00
Annual div
$7.38
5Y div CAGR
32.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$101.1K
Annual income
$28,834.19
Full SSREF calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — SSREF vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSSREFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SSREF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SSREF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SSREF
Annual income on $10K today (after 15% tax)
$397.24/yr
After 10yr DRIP, annual income (after tax)
$24,509.06/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, SSREF beats the other by $2,642.19/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SSREF + ABBV for your $10,000?

SSREF: 50%ABBV: 50%
100% ABBV50/50100% SSREF
Portfolio after 10yr
$102.9K
Annual income
$27,279.95/yr
Blended yield
26.51%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SSREF
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
1.7
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SSREF buys
0
ABBV buys
0
No recent congressional trades found for SSREF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSSREFABBV
Forward yield4.67%3.12%
Annual dividend / share$7.38$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR32.6%40.6%
Portfolio after 10y$101.1K$104.7K
Annual income after 10y$28,834.19$25,725.73
Total dividends collected$72.4K$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: SSREF vs ABBV ($10,000, DRIP)

YearSSREF PortfolioSSREF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,320$619.70$11,559$438.51$239.00ABBV
2$12,981$869.31$13,494$640.86$513.00ABBV
3$15,126$1,235.43$15,951$945.97$825.00ABBV
4$17,968$1,783.89$19,152$1,413.89$1.2KABBV
5$21,852$2,626.16$23,443$2,146.38$1.6KABBV
6$27,340$3,957.95$29,391$3,321.96$2.1KABBV
7$35,390$6,136.64$37,948$5,265.87$2.6KABBV
8$47,712$9,844.16$50,795$8,596.74$3.1KABBV
9$67,498$16,446.75$71,034$14,549.41$3.5KABBV
10$101,057$28,834.19$104,715$25,725.73$3.7KABBV

SSREF vs ABBV: Complete Analysis 2026

SSREFStock

Swiss Re AG, together with its subsidiaries, provides wholesale reinsurance, insurance, other insurance-based forms of risk transfer, and other insurance-related services worldwide. The company operates through Property & Casualty Reinsurance, Life & Health Reinsurance, and Corporate Solutions. The Property & Casualty Reinsurance segment underwrites property reinsurance, including property, credit and surety, engineering, aviation, marine, agriculture, retakaful, and facultative reinsurance solutions; and casualty reinsurance, such as liability, motor, worker's compensation, personal accident, management and professional liability, cyber, and facultative reinsurance solutions. The Life & Health Reinsurance segment underwrites life and health insurance products. The Corporate Solutions segment offers standard risk transfer covers and multi-line programs to customized solutions. It serves stock and mutual insurance companies, public sector and governmental entities, mid-sized and large corporations, and individuals. Swiss Re AG was founded in 1863 and is headquartered in Zurich, Switzerland.

Full SSREF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SSREF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SSREF vs SCHDSSREF vs JEPISSREF vs OSSREF vs KOSSREF vs MAINSSREF vs JNJSSREF vs MRKSSREF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.